

Christopher Thomas Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/718741/publications.pdf>

Version: 2024-02-01

55
papers

953
citations

489802

18
h-index

563245

28
g-index

63
all docs

63
docs citations

63
times ranked

1104
citing authors

#	ARTICLE	IF	CITATIONS
1	How Ethics Can Better Anticipate the Consequences of Emerging Biotechnologies. American Journal of Bioethics, 2022, 22, 46-48.	0.5	4
2	Beyond babies: Implications of human genome editing for women, children, and families. Accountability in Research, 2021, , 1-10.	1.6	1
3	Voices of biotech leaders. Nature Biotechnology, 2021, 39, 654-660.	9.4	1
4	Toward anticipatory governance of human genome editing: a critical review of scholarly governance discourse. Journal of Responsible Innovation, 2021, 8, 382-420.	2.3	21
5	Scientific and Ethical Uncertainties in Brain Organoid Research. American Journal of Bioethics, 2021, 21, 48-51.	0.5	10
6	A matter of life and longer life. Journal of Aging Studies, 2019, 50, 100800.	0.7	5
7	What to Expect When Expecting CRISPR Baby Number Four. American Journal of Bioethics, 2019, 19, 7-9.	0.5	21
8	Prioritizing Women's Health in Germline Editing Research. AMA Journal of Ethics, 2019, 21, E1071-1078.	0.4	4
9	Off-Target Effects of a Defense of Denial. American Journal of Bioethics, 2018, 18, 22-24.	0.5	1
10	The rise of the ethical license. Nature Biotechnology, 2017, 35, 22-24.	9.4	39
11	Revisiting the Warnock rule. Nature Biotechnology, 2017, 35, 1029-1042.	9.4	47
12	Gene therapy's out-of-body experience. Nature Biotechnology, 2016, 34, 600-607.	9.4	10
13	The ethics of publishing human germline research. Nature Biotechnology, 2015, 33, 590-592.	9.4	14
14	Patenting parthenotes in the US and Europe. Nature Biotechnology, 2015, 33, 1232-1234.	9.4	0
15	Selling long life. Nature Biotechnology, 2015, 33, 31-40.	9.4	15
16	Backward by Design: <i>Building ELSI into a Stem Cell Science Curriculum</i>. Hastings Center Report, 2015, 45, 26-32.	0.7	8
17	Stem Cell Patents after the America Invents Act. Cell Stem Cell, 2015, 16, 461-464.	5.2	8
18	Lift NIH restrictions on chimera research. Science, 2015, 350, 640-640.	6.0	17

#	ARTICLE	IF	CITATIONS
19	Money and Morals. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 19, 297-315.	0.8	8
20	Wrongful Termination: Lessons From the Geron Clinical Trial. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1398-1401.	1.6	49
21	Great Expectations: Autism Spectrum Disorder and Induced Pluripotent Stem Cell Technologies. <i>Stem Cell Reviews and Reports</i> , 2014, 10, 145-150.	5.6	13
22	The time is ripe for an ethics of entrepreneurship. <i>Nature Biotechnology</i> , 2014, 32, 316-318.	9.4	5
23	Position Statement on the Provision and Procurement of Human Eggs for Stem Cell Research. <i>Cell Stem Cell</i> , 2013, 12, 285-291.	5.2	8
24	Dear Student: Stem Cell Scientists's Advice to the Next Generation. <i>Cell Stem Cell</i> , 2013, 12, 652-655.	5.2	5
25	The Race Is On: Human Embryonic Stem Cell Research Goes Global. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 1043-1047.	5.6	7
26	Personal medicine—the new banking crisis. <i>Nature Biotechnology</i> , 2012, 30, 141-147.	9.4	83
27	Expand and Regularize Federal Funding for Human Pluripotent Stem Cell Research. <i>Journal of Policy Analysis and Management</i> , 2012, 31, 714-722.	1.1	4
28	Democracy Derived? New Trajectories in Pluripotent Stem Cell Research. <i>Cell</i> , 2011, 145, 820-826.	13.5	28
29	Donation of Embryos for Human Development and Stem Cell Research. <i>Cell Stem Cell</i> , 2011, 8, 360-362.	5.2	22
30	The European Court of Justice Ruling in <i>Brüstle v. Greenpeace</i> : The Impacts on Patenting of Human Induced Pluripotent Stem Cells in Europe. <i>Cell Stem Cell</i> , 2011, 9, 502-503.	5.2	6
31	Unsettled expectations: how recent patent decisions affect biotech. <i>Nature Biotechnology</i> , 2011, 29, 229-230.	9.4	6
32	Pluripotent patents make prime time: an analysis of the emerging landscape. <i>Nature Biotechnology</i> , 2010, 28, 557-559.	9.4	16
33	Federal policy and the use of pluripotent stem cells. <i>Nature Methods</i> , 2010, 7, 866-867.	9.0	14
34	The Language of Hope: Therapeutic Intent in Stem-Cell Clinical Trials. <i>American Journal of Bioethics Primary Research</i> , 2010, 1, 4-11.	1.5	9
35	Response to Open Peer Commentaries on "Stem Cell Tourism and the Power of Hope." <i>American Journal of Bioethics</i> , 2010, 10, W1-W3.	0.5	1
36	Stem Cell Tourism and the Power of Hope. <i>American Journal of Bioethics</i> , 2010, 10, 16-23.	0.5	92

#	ARTICLE	IF	CITATIONS
37	The Stem-Cell Century: A New Epoch and Fresh Challenge. <i>Perspectives in Biology and Medicine</i> , 2009, 52, 126-133.	0.3	0
38	The Practical Consequences of a National Human Embryonic Stem Cell Registry. <i>Stem Cell Reviews and Reports</i> , 2009, 5, 315-318.	5.6	4
39	Stem cell transplants: the power of peer-to-peer. <i>Nature Biotechnology</i> , 2009, 27, 21-22.	9.4	10
40	We must reverse the Bush legacy of stem-cell problems. <i>Nature</i> , 2009, 460, 33-33.	13.7	3
41	And then there were two: use of hESC lines. <i>Nature Biotechnology</i> , 2009, 27, 696-697.	9.4	39
42	Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where. <i>Cell Stem Cell</i> , 2009, 4, 107-110.	5.2	29
43	Ethics Report on Interspecies Somatic Cell Nuclear Transfer Research. <i>Cell Stem Cell</i> , 2009, 5, 27-30.	5.2	10
44	Patenting pluripotency: the next battle for stem cell intellectual property. <i>Nature Biotechnology</i> , 2008, 26, 393-395.	9.4	24
45	Challenges to Human Embryonic Stem Cell Patents. <i>Cell Stem Cell</i> , 2008, 2, 13-17.	5.2	27
46	The road to pluripotency: the research response to the embryonic stem cell debate. <i>Human Molecular Genetics</i> , 2008, 17, R3-R9.	1.4	16
47	Stem cells: new frontiers of ethics, law, and policy. <i>Neurosurgical Focus</i> , 2008, 24, E24.	1.0	11
48	Weighing risks and rewards en route to the clinic. <i>Nature Reports Stem Cells</i> , 2008, , .	0.1	2
49	Mice with a human touch. <i>Nature Biotechnology</i> , 2007, 25, 1075-1077.	9.4	21
50	Overhauling clinical trials. <i>Nature Biotechnology</i> , 2007, 25, 287-292.	9.4	30
51	Chimeras in the crosshairs. <i>Nature Biotechnology</i> , 2006, 24, 487-490.	9.4	12
52	The paths around stem cell intellectual property. <i>Nature Biotechnology</i> , 2006, 24, 411-413.	9.4	20
53	Chasing a cellular fountain of youth. <i>Nature Biotechnology</i> , 2005, 23, 807-815.	9.4	22
54	The zinc finger nuclease monopoly. <i>Nature Biotechnology</i> , 2005, 23, 915-918.	9.4	38

#	ARTICLE	IF	CITATIONS
55	The problem with potency. <i>Nature Biotechnology</i> , 2005, 23, 1037-1039.	9.4	25